In breast cancer, mutations in PIK3CA also have prognostic relevance and are associated with better invasive disease-free survival (HR: 0.77; p < 0.001), with evidence for a more substantial effect in the first 5 years (0 to 5 years: HR: 0.73; p < 0.001; 5 to 10 years: HR: 0.82; p = 0.037) [24]. Here, PIK3CA is linked to breast carcinoma.